Mei-Ju Su

TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.

TL;DR: The ability to interrogate ex vivo response to PD-1 blockade using murine- and patient-derived organotypic tumor spheroids (MDOTS/PDOTS) is demonstrated, which represents a novel platform to evaluate ICB using established murine models as well as clinically relevant patient specimens.

TL;DR: A set of ready-to-use tools for profiling fresh and frozen clinical tumor samples using scRNA-Seq and snRNA- Seq facilitates the implementation of single-cell technologies in clinical settings and the construction ofsingle-cell tumor atlases.

TL;DR: Significant inter-patient variability is found in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations, which contributes to resolving the HSGOC landscape and provides a resource for the development of novel therapeutic approaches.

TL;DR: This work provides direct guidance across a broad range of tumors, including criteria for testing and selecting methods from the toolbox for other tumors, thus paving the way for charting tumor atlases.